Ingevity stock has delivered a strong 81.0% return over the past year, yet the current pricing appears expensive on earnings multiples and the broader valuation checks point to a more mixed picture rather than a clear bargain.

• Over the last 1 year, Ingevity has returned 81.0%, which puts more pressure on the current share price to be supported by future execution.
• Expectations for Ingevity to continue converting revenue into solid cash flow can support the current valuation, while any setback in margins or balance sheet strain may quickly challenge today’s multiples.
• With a value score of 3 out of 6, Ingevity does not screen as clearly cheap or clearly expensive across the broader set of valuation checks.

The key question now is whether Ingevity’s recent share price strength leaves enough room for error at today’s valuation.

Is Ingevity Getting Expensive on Earnings?

The P/E multiple is a useful way to see what you are paying for each dollar of Ingevity earnings. On this measure, the stock stands out. Ingevity trades on a P/E of about 100.9x, compared with an industry average near 25.0x for Chemicals peers and a peer group average around 23.4x. That is a very large premium to both the sector and similar companies.

The fair P/E ratio from the model is about 32.7x. The gap between this fair level and the current 100.9x suggests the model is heavily penalising Ingevity for its risk profile or the quality and consistency of current earnings. Rather than treating 32.7x as a precise target, it is better read as a signal that, on earnings alone, the stock screens as very expensive and allows limited room for earnings disappointment at the current share price.

On the P/E multiple, Ingevity stock currently screens as overvalued compared with both its tailored fair ratio and the wider Chemicals industry.

The Ingevity Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Ingevity aim to connect the valuation puzzle above with the specific business outcomes that would need to play out for today's price to prove too high or too low. Each narrative spells out a different set of assumptions for Ingevity's growth, margins and earnings, and links these to a fair value estimate tied to that story's potential catalysts and risks, so you can track which version seems closer to reality over time.

You can add your voice to the Simply Wall St community by sharing a Narrative on Ingevity that lays out a clear, number driven view on where its growth, margins and execution go from here. Set out your thesis in one place and track how it holds up as future results and market reactions come through.

Do you think there's more to the story for Ingevity? Head over to our Community to see what others are saying!

The Bottom Line

Ingevity now trades on an earnings multiple that appears clearly overvalued compared with sector peers and the stock’s own tailored fair P/E signal. That does not rule out further upside, but it does mean the market already prices in a substantial degree of confidence in Ingevity’s ability to sustain margins and cash generation. The key question from here is whether execution and balance sheet discipline can remain strong enough to justify this premium, or whether any disappointment prompts a reset in the multiple.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.